Literature DB >> 21258423

Lack of IL-21 signal attenuates graft-versus-leukemia effect in the absence of CD8 T-cells.

A Meguro1, K Ozaki, K Hatanaka, I Oh, K Sudo, T Ohmori, H Matsu, R Tatara, K Sato, Y Sakata, S Nakae, W J Leonard, K Ozawa.   

Abstract

Previously, we have shown that IL-21R(-/-) splenocytes ameliorate GVHD as compared with wild-type splenocytes. Here, we investigated whether or not IL-21R(-/-) splenocytes diminish the graft-versus-leukemia (GVL) effect. Surprisingly, IL-21R(-/-) splenocytes efficiently eliminate leukemic cells as well as wild-type splenocytes, suggesting the retention of GVL effects in the absence of IL-21 signaling. To compare the GVL effect between IL-21R(-/-) and wild-type cells, we titrated the number of splenocytes required for the elimination of leukemic cells and found that the threshold of GVL effect was obtained between 5 × 10(5) and 5 × 10(6) with both types of splenocytes. Cotransplantation with CD8-depleted splenocytes but not with purified CD8 T-cells resulted in a significant reduction in anti-leukemic effect of IL-21R(-/-) cells compared with wild-type cells, suggesting that the lack of IL-21 signaling primarily impairs CD4 T-cell rather than CD8 T-cell function and the comparable GVL effect with IL-21R(-/-) bulk splenocytes results from cooperative compensation by CD8 T-cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21258423      PMCID: PMC3401481          DOI: 10.1038/bmt.2010.342

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  32 in total

Review 1.  Cytokine and cytokine receptor pleiotropy and redundancy.

Authors:  Katsutoshi Ozaki; Warren J Leonard
Journal:  J Biol Chem       Date:  2002-06-18       Impact factor: 5.157

2.  LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.

Authors:  K R Cooke; A Gerbitz; J M Crawford; T Teshima; G R Hill; A Tesolin; D P Rossignol; J L Ferrara
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Altered effector CD4+ T cell function in IL-21R-/- CD4+ T cell-mediated graft-versus-host disease.

Authors:  Iekuni Oh; Katsutoshi Ozaki; Akiko Meguro; Keiko Hatanaka; Masanori Kadowaki; Haruko Matsu; Raine Tatara; Kazuya Sato; Yoichiro Iwakura; Susumu Nakae; Katsuko Sudo; Takanori Teshima; Warren J Leonard; Keiya Ozawa
Journal:  J Immunol       Date:  2010-06-23       Impact factor: 5.422

4.  Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.

Authors:  Pavan Reddy; Takanori Teshima; Gerhard Hildebrandt; Ulrich Duffner; Yoshinobu Maeda; Kenneth R Cooke; James L M Ferrara
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

5.  Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.

Authors:  Yong-Guang Yang; Jin Qi; Min-Guang Wang; Megan Sykes
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

6.  Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.

Authors:  J Parrish-Novak; S R Dillon; A Nelson; A Hammond; C Sprecher; J A Gross; J Johnston; K Madden; W Xu; J West; S Schrader; S Burkhead; M Heipel; C Brandt; J L Kuijper; J Kramer; D Conklin; S R Presnell; J Berry; F Shiota; S Bort; K Hambly; S Mudri; C Clegg; M Moore; F J Grant; C Lofton-Day; T Gilbert; F Rayond; A Ching; L Yao; D Smith; P Webster; T Whitmore; M Maurer; K Kaushansky; R D Holly; D Foster
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

7.  IL-21 is critical for GVHD in a mouse model.

Authors:  A Meguro; K Ozaki; I Oh; K Hatanaka; H Matsu; R Tatara; K Sato; W J Leonard; K Ozawa
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

8.  Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.

Authors:  Shawn G Clouthier; Kenneth R Cooke; Takanori Teshima; Kathleen P Lowler; Chen Liu; Kevin Connolly; James L M Ferrara
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

9.  A critical role for IL-21 in regulating immunoglobulin production.

Authors:  Katsutoshi Ozaki; Rosanne Spolski; Carl G Feng; Chen-Feng Qi; Jun Cheng; Alan Sher; Herbert C Morse; Chengyu Liu; Pamela L Schwartzberg; Warren J Leonard
Journal:  Science       Date:  2002-11-22       Impact factor: 47.728

10.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Authors:  Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

View more
  10 in total

1.  Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Authors:  Keli L Hippen; Christoph Bucher; Dawn K Schirm; Amanda M Bearl; Ty Brender; Kathy A Mink; Kimberly S Waggie; Regis Peffault de Latour; Anne Janin; Julie M Curtsinger; Stacey R Dillon; Jeffrey S Miller; Gerard Socie; Bruce R Blazar
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.

Authors:  Alan M Hanash; Lucy W Kappel; Nury L Yim; Rebecca A Nejat; Gabrielle L Goldberg; Odette M Smith; Uttam K Rao; Lindsay Dykstra; Il-Kang Na; Amanda M Holland; Jarrod A Dudakov; Chen Liu; George F Murphy; Warren J Leonard; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2011-05-19       Impact factor: 22.113

Review 3.  The IL-17 differentiation pathway and its role in transplant outcome.

Authors:  Jonathan S Serody; Geoffrey R Hill
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

4.  IL-21 accelerates xenogeneic graft-versus-host disease correlated with increased B-cell proliferation.

Authors:  Xiaoran Wu; Yi Tan; Qiao Xing; Shengdian Wang
Journal:  Protein Cell       Date:  2013-11-10       Impact factor: 14.870

Review 5.  The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.

Authors:  Hui Wang; Yong-Guang Yang
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

Review 6.  Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease.

Authors:  F Malard; B Gaugler; B Lamarthee; M Mohty
Journal:  Mucosal Immunol       Date:  2016-01-27       Impact factor: 7.313

Review 7.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

Review 8.  IL-21 Signaling in Immunity.

Authors:  Warren J Leonard; Chi-Keung Wan
Journal:  F1000Res       Date:  2016-02-26

9.  Evaluation of Serum Interleukin-21 and HLA-C1 Polymorphism in Pediatrician Hematopoietic Stem Cell Transplantation for Early Diagnosis of Acute Graft-Versus-Host Disease

Authors:  N Sehati; P Kokhaei; A Motevalizade Ardekani; R Tootoonchian; F Pak
Journal:  Iran Biomed J       Date:  2017-06-19

Review 10.  T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.

Authors:  Hua Jiang; Denggang Fu; Alan Bidgoli; Sophie Paczesny
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.